Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025

This enduring is designed to assist veterans’ affairs-associated members of the multi-disciplinary oncology care team in evaluating current developments in the use of novel bispecific antibody therapies in later-line management of Non-Hodgkin’s Lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and current efficacy and safety data associated with adverse event management in NHL.

RELEASED DATE: January 18, 2024
EXPIRATION DATE: January 18, 2025

This virtually live educational activity focuses on leveraging targetable mutations for cancer-directed therapy through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in Non-Hodgkin’s Lymphoma.

RELEASED DATE: July 20, 2023
EXPIRATION DATE: July 20, 2024

This enduring TeleECHO educational series is designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin's lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as discussion of best practices for multidisciplinary management of B-cell NHL to improve long-term clinical outcomes.

RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025